Eligibility for Human Leukocyte Antigen-Based Therapeutics by Race and Ethnicity.

ABSTRACT:

Importance

The development of therapeutics for patients who are positive for specific human leukocyte antigen (HLA) subtypes evokes the question of whether certain racial and ethnic groups are more or less likely to be eligible for novel products.

Objective

To determine whether racial and ethnic inequities were present with regard to trial eligibility in trials investigating a therapeutic restricted to patients with specific HLA subtypes.

Design, setting, and participants

This cross-sectional study included all clinical trials registered in ClinicalTrials.gov through March 18, 2022, that investigated an interventional study of a therapeutic strategy and restricted participants to those with at least 1 HLA subtype. Data were analyzed from May 8 to July 1, 2022.

Main

SUBMITTER: Olivier T 

PROVIDER: S-EPMC10603498 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature